PGR and breast cancer: All metformin-treated breast cancer cell lines showed a decreased proliferation 24 h and 48 h post-treatment, however, we observed that the proliferation of the HER2+/ER−/PR- breast cancer cell line was the least affected by metformin 48 h post-treatment (Fig. 1b).